EE81 Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab (NIVO+IPI) Versus Pembrolizumab Plus Axitinib (PEM+AXI) for the First-Line Treatment of Intermediate- and Poor (I/P)-Risk Advanced Renal Cell Carcinoma Patients in Colombia

Autor: Dhanji, N., Van De Wetering, G., Guiot, V., Barco, V., Mejia, A., May, J.R., Garcia, J., Dyer, M.
Zdroj: In Value in Health June 2023 26(6) Supplement:S74-S74
Databáze: ScienceDirect
Externí odkaz: